Aileron Therapeutics Q1 2024 GAAP EPS $(0.86) Misses $(0.14) Estimate
Portfolio Pulse from Benzinga Newsdesk
Aileron Therapeutics (NASDAQ:ALRN) reported a Q1 2024 GAAP EPS of $(0.86), significantly missing the analyst consensus estimate of $(0.14) by 514.29%.
May 15, 2024 | 9:13 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Aileron Therapeutics reported a Q1 2024 GAAP EPS of $(0.86), missing the analyst consensus estimate of $(0.14) by a significant margin of 514.29%. This substantial earnings miss is likely to negatively impact the stock price in the short term.
The significant earnings miss indicates that the company's financial performance is much worse than expected, which is likely to lead to a negative reaction from investors and a decline in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100